Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Lexicon Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LXRX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 41% a week.
Volatility Over Time: LXRX's weekly volatility has increased from 22% to 41% over the past year.
7 Day Return
1 Year Return
Return vs Industry: LXRX exceeded the US Biotechs industry which returned 45.9% over the past year.
Return vs Market: LXRX exceeded the US Market which returned 23.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Lexicon Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHow Is Lexicon Pharmaceuticals' (NASDAQ:LXRX) CEO Paid Relative To Peers?
2 months ago | Simply Wall StNews Flash: Analysts Just Made A Stunning Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts
3 months ago | Simply Wall StNeed To Know: Analysts Are Much More Bullish On Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Revenues
Is Lexicon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LXRX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LXRX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LXRX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: LXRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LXRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LXRX is overvalued based on its PB Ratio (11.3x) compared to the US Biotechs industry average (4.4x).
How is Lexicon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LXRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LXRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LXRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LXRX's revenue (7.7% per year) is forecast to grow slower than the US market (10.6% per year).
High Growth Revenue: LXRX's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LXRX is forecast to be unprofitable in 3 years.
How has Lexicon Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LXRX is currently unprofitable.
Growing Profit Margin: LXRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LXRX is unprofitable, but has reduced losses over the past 5 years at a rate of 19.7% per year.
Accelerating Growth: Unable to compare LXRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LXRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: LXRX has a negative Return on Equity (-118.92%), as it is currently unprofitable.
How is Lexicon Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: LXRX's short term assets ($121.9M) exceed its short term liabilities ($78.9M).
Long Term Liabilities: LXRX's short term assets ($121.9M) exceed its long term liabilities ($12.4M).
Debt to Equity History and Analysis
Debt Level: LXRX's debt to equity ratio (23.2%) is considered satisfactory.
Reducing Debt: LXRX's debt to equity ratio has reduced from 53.1% to 23.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable LXRX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: LXRX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 5.4% per year.
What is Lexicon Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LXRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LXRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LXRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LXRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LXRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lonnel Coats (55 yo)
Mr. Lonnel Coats has been the Chief Executive Officer and President of Lexicon Pharmaceuticals, Inc., since July 7, 2014. Mr. Coats served as an Executive Vice President, President of Americas Region at Ei...
CEO Compensation Analysis
Compensation vs Market: Lonnel's total compensation ($USD3.87M) is above average for companies of similar size in the US market ($USD2.40M).
Compensation vs Earnings: Lonnel's compensation has increased whilst the company is unprofitable.
|Executive VP of Corporate & Administrative Affairs and CFO||10.67yrs||US$1.61m||0.082% |
|Executive Vice President of Research & Development||4.67yrs||US$1.68m||0.049% |
|Consultant & Independent Director||19.92yrs||US$88.76k||0.012% |
|Vice President of Finance & Accounting||13.17yrs||US$508.34k||0.046% |
|VP, General Counsel & Secretary||10.67yrs||no data||0.035% |
|Executive Director of Corporate Communications & Patient Advocacy||20yrs||no data||no data|
|Executive Vice President of Commercial Supply Operations||19.5yrs||US$1.07m||0.074% |
Experienced Management: LXRX's management team is seasoned and experienced (11.9 years average tenure).
|Consultant & Independent Director||19.92yrs||US$88.76k||0.012% |
|Independent Chairman of the Board||8.92yrs||US$118.18k||0.23% |
|Independent Director||20.83yrs||US$107.18k||0.040% |
|Independent Director||13.42yrs||US$90.96k||0.012% |
|Independent Director||13.42yrs||US$84.55k||0.10% |
|Independent Director||13.33yrs||US$96.87k||0.012% |
|Chairman of Medical Advisory Board & Independent Director||17.83yrs||US$84.55k||0.012% |
|Independent Director||16.17yrs||US$105.98k||0.012% |
Experienced Board: LXRX's board of directors are seasoned and experienced ( 13.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.4%.
Lexicon Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Lexicon Pharmaceuticals, Inc.
- Ticker: LXRX
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.197b
- Shares outstanding: 140.70m
- Website: https://www.lexpharma.com
Number of Employees
- Lexicon Pharmaceuticals, Inc.
- 8800 Technology Forest Place
- The Woodlands
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LXRX||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Apr 2000|
|LX31||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Apr 2000|
|LX31||MUN (Boerse Muenchen)||Yes||Common Shares||DE||EUR||Apr 2000|
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/23 23:52|
|End of Day Share Price||2021/01/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.